Clozapine and agranulocytosis: Should treatment be continued?;Granulocytopenie bij clozapine: Doorgaan of stoppen met behandeling

Tijdschrift voor Psychiatrie

Volumn 49, Issue 8, 2007, Pages 575-579

  Bogers, J P A M ^a,b  

^a GGZ Haagstreek   (Netherlands)

^b NONE

Author keywords

Agranulocytosis; Clozapine; Neutropenia

Indexed keywords

CITALOPRAM; CLOZAPINE; LITHIUM CARBONATE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TEMAZEPAM;

ADULT; AGRANULOCYTOSIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; DEMOGRAPHY; DRUG BLOOD LEVEL; DRUG WITHDRAWAL; ELECTROCONVULSIVE THERAPY; FEMALE; FOOD AND DRUG ADMINISTRATION; GRANULOCYTOPENIA; HUMAN; LABORATORY TEST; MALE; NEUTROPENIA; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA;

ADULT; AGRANULOCYTOSIS; ANTIPSYCHOTIC AGENTS; CLOZAPINE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUTROPENIA;

EID: 34548615884     PISSN: 03037339     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Ahn, Y.M., Jeong, S.H., Jang, H.S., e.a. (2004). Experience of maintaining clozapine medication in patients with 'red-alert zone' neutropenia: long-term follow-up results. International Clinical Psychopharmacology, 19, 97-101.
2. Alvir, J.M.J., & Lieberman, J.A. (1994). Agranulocytosis: incidence and risk factors. Journal of clinical Psychiatry, 55(Suppl. B), 137-138.
3. Bijl, J.R. van der, Arends, J., Slooff, C.J., e.a. (2005). Rechallenge met clozapine na granulocytopenic of agranulocytose; een verantwoorde interventie bij patiënten met een therapieresistente psychose? In C.J. Slooff, F. Withaar & M. van der Gaag (Red.), Terugvalpreventie bij schizofrenie en aanverwante psychosen (pp. 423-448). Assen/Den Haag/Groningen/Amersfoort/Utrecht: Kenniscentrum Schizofrenie Nederland.
4. European Agency for the Evaluation of Medicinal Products. (2005). http://www.emea.eu.int/pdfs/human/referral/603402en.pdf.
5. Fitzsimons, J., Berk, M., Lambert, T., e.a. (2005). A review of clozapine safety. Expert Opinion on Drug Safety, 4, 731-744.
6. Getson, S.L (1993). Clozapine - deciphering the risks. New England Journal of Medicine, 329, 204-205.
7. Hägg, S., Rosenius, S., & Spigset, O. (2003). Long-term combination treatment with clozapine and filgrastim in patients with clozapine-induced agranulocytosis. International Clinical Psychopharmacology, 18, 173-174.
8. Heimpel, H. (1991). The diseases. In: D.W. Kaufman, J.P. Kelly, M. Levy e.a. (Red.), The drug etiology of agranulocytosis and plastic anemia (pp. 27-53). New York/Oxford: Oxford University Press.
9. Honigfeld, G., Arellano, F., Sethi, J., e.a. (1998). Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. Journal of Clinical Psychiatry, 59(Suppl. 3), 3-7.
10. Hummer, M., Kurz, M., Barnas, C., e.a. (1992). Transient neutropenia induced by clozapine. Psychopharmacology Bulletin, 28, 287-290.
11. Melick, E.J.M. van, Touw, D.J., & Haak, H.L. (1995). Agranulocytose door clozapine: het belang van leukocytencontrole en het nut van bloedgroeifactoren. Nederlands Tijdschrift voor Geneeskunde, 139, 2437-2440.
12. Schulte, P.F.J., & Clozapine Plus Werkgroep (2004). Clozapine - Toelichting bij een richtlijn. http://www.clozapinepluswerkgroep.nl.
13. Sperner-Unterweger, B., Czeipek, I., Gaggl, S., e.a. (1998). Treatment of severe clozapine-induced neutropenia with granulocyte colony-stimulating factor (G-CSF). Remission despite continuous treatment with clozapine. British Journal of Psychiatry, 172, 82-84.
14. Wahlbeck, K., Cheine, K, Essali, M.A., e.a. (1999). Clozapine versus typical neuroleptic medication for schizophrenia. Oxford: Cochrane Library.